1. Articles in category: Treatment

    1-24 of 184 1 2 3 4 5 6 7 8 »
    1. PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma.

      Mol Cancer Ther. 2018 Feb 13;:

      Authors: Brunen D, de Vries RC, Lieftink C, Beijersbergen RL, Bernards R

      Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets.

      Read Full Article
    2. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    3. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    4. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 Jan 19;:

      Authors: Ceylan K, Jahns LJ, Lode BN, Ehlert K, Kietz S, Troschke-Meurer S, Siebert N, Lode HN

      Read Full Article
      Mentions: Antibody Treatment
    5. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 in patients with high-risk neuroblastoma

      The monoclonal anti-GD2 antibody ch14.18/CHO in combination with IL-2 is active and effective in high-risk neuroblastoma (NB) patients. Here, we investigated the inflammatory response and treatment tolerance of long-term infusion (LTI) of ch14.18/CHO (10 × 10 mg/m2; 24 hr) in combination with subcutaneous (s.c.) IL-2 in a single center program.

      Read Full Article
      Mentions: Antibody Treatment
    6. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma.

      Cancer Gene Ther. 2016 Nov;23(11):371-372

      Authors: Mohammadi M, Goodarzi M, Jaafari MR, Mirzaei HR, Mirzaei H

      Abstract Neuroblastoma (NB) is known as a pediatric neoplasm that is associated with variable histopathological features. The use of biomarkers contributes to the monitoring and treatment of various malignancies such as NB.

      Read Full Article
    7. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    8. FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      FTY-720 induces apoptosis in neuroblastoma via multiple signaling pathways.

      Oncotarget. 2017 Dec 15;8(66):109985-109999

      Authors: Lange I, Espinoza-Fuenzalida I, Ali MW, Serrano LE, Koomoa DT

      Abstract Neuroblastoma (NB) is the most common extra-cranial pediatric solid tumor. High-risk NB is difficult to treat due to the lack of response to current therapies and aggressive disease progression.

      Read Full Article
    9. mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      ACS Appl Mater Interfaces. 2018 Jan 03;:

      Authors: Haimov E, Weitman H, Polani S, Schori H, Zitoun D, Shefi O

      Abstract Photodynamic Therapy (PDT) is a promising therapeutic modality for cancer. However, current protocols using bare drugs suffer from several limitations that impede its beneficial clinical effects. Here, we introduce a new approach for an efficient PDT treatment.

      Read Full Article
    10. Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance.

      Molecular and functional analysis of anchorage independent, treatment-evasive neuroblastoma tumorspheres with enhanced malignant properties: A possible explanation for radio-therapy resistance.

      PLoS One. 2018;13(1):e0189711

      Authors: Abou-Antoun TJ, Nazarian J, Ghanem A, Vukmanovic S, Sandler AD

      Read Full Article
      Mentions: Treatment MYCN
    11. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      The European Commission has...

      Read Full Article
    12. Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Early and late effects of pharmacological ALK inhibition on the neuroblastoma transcriptome.

      Oncotarget. 2017 Dec 05;8(63):106820-106832

      Authors: Claeys S, Denecker G, Cannoodt R, Kumps C, Durinck K, Speleman F, De Preter K

      Abstract Background: Neuroblastoma is an aggressive childhood malignancy of the sympathetic nervous system. Despite multi-modal therapy, survival of high-risk patients remains disappointingly low, underscoring the need for novel treatment strategies.

      Read Full Article
      Mentions: Treatment ALK MYCN
    13. Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Indian J Med Res. 2017 Aug;146(2):216-223

      Authors: Seth R, Singh A, Seth S, Sapra S

      Abstract BACKGROUND & OBJECTIVES: With improved survival of childhood cancer patients, the number of long-term cancer survivors is increasing. Some studies have assessed the long-term morbidity after childhood cancer treatment in the developing countries.

      Read Full Article
    14. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      Read Full Article
    15. Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Review: The role of radiolabeled DOTA-conjugated peptides for imaging and treatment of childhood neuroblastoma.

      Curr Radiopharm. 2017 Dec 14;:

      Authors: Alexander N, Vali R, Ahmadzadehfar H, Shammas A, Baruchel S

      Abstract Childhood neuroblastoma is a heterogenous disease with varied clinical presentation and biology requiring different approaches to investigation and management.

      Read Full Article
    16. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Drugs Today (Barc). 2017 Sep;53(9):469-476

      Authors: Greenwood K, Foster JH

      Abstract Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy.

      Read Full Article
      Mentions: Antibody Treatment
    17. Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

      Read Full Article
      Mentions: Treatment GvHD
    18. Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.

      Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey.

      EJNMMI Phys. 2017 Dec 04;4(1):28

      Authors: Sjögreen Gleisner K, Spezi E, Solny P, Gabina PM, Cicone F, Stokke C, Chiesa C, Paphiti M, Brans B, Sandström M, Tipping J, Konijnenberg M, Flux G

      Read Full Article
      Mentions: Radiotherapy
    19. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      J Pediatr Surg. 2017 Nov 09;:

      Authors: Amano H, Uchida H, Tanaka Y, Tainaka T, Mori M, Oguma E, Kishimoto H, Kawashima H, Arakawa Y, Hanada R, Koh K

      Read Full Article
    20. Surgical Treatment of Neuroblastoma.

      Surgical Treatment of Neuroblastoma.

      Isr Med Assoc J. 2017 Nov;19(11):691-695

      Authors: Ben Barak A, Golan H, Waldman D, Arkovitz MS

      Abstract BACKGROUND: Neuroblastoma is the most common non-central nervous system (CNS) solid malignant tumor in children. The surgical treatment of high-risk neuroblastoma presents a challenge, and the benefits of aggressive surgical resection have been called into question. OBJECTIVES: To examine our experience with surgical resection of neuroblastoma.

      Read Full Article
      Mentions: Treatment
    21. Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.

      Oncoimmunology. 2017;6(11):e1358331

      Authors: Cheung IY, Kushner BH, Modak S, Basu EM, Roberts SS, Cheung NV

      Read Full Article
      Mentions: Antibody
    1-24 of 184 1 2 3 4 5 6 7 8 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. General Informations in the News

    1. (3 articles) Treatment
  4. Treatments in the News

    1. (1 articles) Refractory
    2. (1 articles) Surgery
    3. (1 articles) Relapse